国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2013年
4期
306-308
,共3页
肺肿瘤%肿瘤复发%药物疗法,联合
肺腫瘤%腫瘤複髮%藥物療法,聯閤
폐종류%종류복발%약물요법,연합
Lung neoplasms%Neoplasm recurrence%Drug therapy,combination
目的 探讨伊立替康和顺铂联合沙利度胺治疗复发性小细胞肺癌的疗效与不良反应.方法 选取同时期的62例复发性小细胞肺癌患者,按不平衡指数最小的分配原则随机分为观察组和对照组,观察组采用伊立替康和顺铂联合沙利度胺化疗；对照组采用常规伊立替康和顺铂化疗.比较两组患者疗效及不良反应.结果 观察组和对照组的客观有效率分别为86.7％和63.3％；两组临床疗效比较差异有统计学意义(x2 =8.52,P＜0.05)；主要不良反应为血液学毒性和消化道症状,观察组和对照组比较差异无统计学意义(x2 =0.18,P＞0.05).结论 伊立替康和顺铂联合沙利度胺治疗复发晚期小细胞肺癌,有效率高,不良反应可以耐受.
目的 探討伊立替康和順鉑聯閤沙利度胺治療複髮性小細胞肺癌的療效與不良反應.方法 選取同時期的62例複髮性小細胞肺癌患者,按不平衡指數最小的分配原則隨機分為觀察組和對照組,觀察組採用伊立替康和順鉑聯閤沙利度胺化療；對照組採用常規伊立替康和順鉑化療.比較兩組患者療效及不良反應.結果 觀察組和對照組的客觀有效率分彆為86.7％和63.3％；兩組臨床療效比較差異有統計學意義(x2 =8.52,P＜0.05)；主要不良反應為血液學毒性和消化道癥狀,觀察組和對照組比較差異無統計學意義(x2 =0.18,P＞0.05).結論 伊立替康和順鉑聯閤沙利度胺治療複髮晚期小細胞肺癌,有效率高,不良反應可以耐受.
목적 탐토이립체강화순박연합사리도알치료복발성소세포폐암적료효여불량반응.방법 선취동시기적62례복발성소세포폐암환자,안불평형지수최소적분배원칙수궤분위관찰조화대조조,관찰조채용이립체강화순박연합사리도알화료；대조조채용상규이립체강화순박화료.비교량조환자료효급불량반응.결과 관찰조화대조조적객관유효솔분별위86.7％화63.3％；량조림상료효비교차이유통계학의의(x2 =8.52,P＜0.05)；주요불량반응위혈액학독성화소화도증상,관찰조화대조조비교차이무통계학의의(x2 =0.18,P＞0.05).결론 이립체강화순박연합사리도알치료복발만기소세포폐암,유효솔고,불량반응가이내수.
Objective To investigate the efficacy and toxicity of thalidomide plus irinotecan and cisplatin treatment for recurrent small cell lung cancer.Methods 62 Patients with recurrent small cell lung cancer in the same period were randomly divided into observation group and control group according to the principle of minimum distribution imbalance index.The observation group patients were treated with thalidomide plus irinotecan and cisplatin chemotherapy,and the control group patients were treated with irinotecan and cisplatin chemotherapy.The efficacy and toxicity of the two groups were compared.Results The overall response rate in the group observation was 86.7％ compared with 63.3％ in the control group,and the difference had statistical significance (x2 =8.52,P ＜ 0.05).The major toxicities were hematologic toxicity and gastrointestinal symptoms,and the side effects differences were not statistically significant (x2 =0.18,P ＞ 0.05).Conclusion The treatment of recurrent small cell lung cancer with irinotecan and cisplatin in combination with thalidomide has high efficiency,and the toxicity can be tolerated.
